表紙
市場調查報告書

市場聚光燈:軸性脊椎關節炎 (axSpA)

Market Spotlight: Axial Spondyloarthritis (axSpA)

出版商 Datamonitor Healthcare 商品編碼 930637
出版日期 內容資訊 英文 56 Pages
商品交期: 最快1-2個工作天內
價格
市場聚光燈:軸性脊椎關節炎 (axSpA) Market Spotlight: Axial Spondyloarthritis (axSpA)
出版日期: 2020年02月28日內容資訊: 英文 56 Pages
簡介

2018年時,估計全球20歲以上的成人人口其中590萬人,患有軸性脊椎關節炎 (axSpA) 。並且,預計2027年其數增加到640萬人。現在,各種治療藥臨床實驗進行,其多達到第三階段。相關的資本交易也活性化。

本報告提供軸性脊椎關節炎 (axSpA)的臨床實驗情形與市場趨勢的分析,目前主要已上市/開發平台治療藥概要,及近來的主要臨床實驗的動向,分析師的見解,相關專利的特徵與趨勢,專利資訊,今後10年的患病人數、發病率預測,資本交易趨勢 (授權合約,M&A (企業合併、收購) 等),市場收益額預測等資訊彙整,為您概述為以下內容。

目錄

概要

主要的結論

疾病的背景情況

  • 定義
  • 患者的分類
  • 症狀
  • 危險因素
  • 診斷

治療方法

  • NSAID (非類固醇消炎劑)
  • DMARD (緩解疾病性抗風濕藥)
  • 類固醇
  • 手術

流行病學

  • 軸性脊椎關節炎的流行病學

成藥

開發平台藥物

最近的趨勢和分析師的見解

今後的主要趨勢預測

在法規方面的主要趨勢

成功的概率

許可證與資產取得交易

母體專利

商機

臨床實驗環境:成功的可能性

許可證/資產取得交易

母體專利

商機

臨床試驗情勢

  • 臨床試驗贊助者:各階段
  • 臨床試驗贊助者:各階段 (相)
  • 近幾年趨勢

參考文獻

附錄

目錄
Product Code: DMKC0213546

Overview:

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Datamonitor Healthcare estimates that in 2018, there were 5.9 million prevalent cases of ankylosing spondylitis in adults aged 20 years and older worldwide, and forecasts that number to increase to 6.4 million prevalent cases by 2027. The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, and IL-17. These are commonly administered via the subcutaneous route, with the remainder being intravenous and oral formulations.

The majority of industry-sponsored drugs in active clinical development for axSpA are in Phase III. Therapies in development for axSpA focus on targets such as JAK/STAT, IL-17, tumor necrosis factor-alpha, and granulocytemacrophage colony-stimulating factor (GM-CSF). These drugs are administered via the oral, intravenous, subcutaneous, and topical routes.

High-impact upcoming events in the axSpA space comprise topline Phase III trial results, expected PDUFA dates, a CHMP opinion, a supplemental CHMP opinion, and supplemental CHMP filing results.

The overall likelihood of approval of a Phase I arthritis asset is 9.9%, and the average probability a drug advances from Phase III is 80%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.

There have been 10 licensing and asset acquisition deals involving axSpA drugs during 2015-20. The $132m agreement signed in 2018 between Grunenthal and AstraZeneca for the acquisition of European rights to Nexium and global (ex-US and Japan) rights to Vimovo was the only deal with a publicly released value.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for axSpA have been in the late phases of development, with 82% of trials in Phase III-IV, and only 18% in Phase I-II.

Germany has a substantial lead in the number of axSpA clinical trials globally, while South Korea has the top spot in Asia. Clinical trial activity in the axSpA space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for axSpA, with 27 trials.

Pfizer leads industry sponsors with the highest overall number of clinical trials for axSpA, followed by AbbVie

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • NSAIDs
  • DMARDs
  • Steroids
  • Surgery

EPIDEMIOLOGY

  • Epidemiology of axial spondyloarthritis

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Cosentyx for Axial Spondyloarthritis (November 12, 2019)
  • Rinvoq for Axial Spondyloarthritis (November 12, 2019)
  • Taltz for Axial Spondyloarthritis (November 12, 2019)
  • Inflectra for Axial Spondyloarthritis (September 19, 2019)
  • Cosentyx for Axial Spondyloarthritis (September 17, 2019)
  • Taltz for Axial Spondyloarthritis (April 22, 2019)
  • SensoReady Injector Pen for Axial Spondyloarthritis (April 9, 2019)
  • Taltz for Axial Spondyloarthritis (October 22, 2018)
  • Taltz for Axial Spondyloarthritis (October 20, 2018)
  • Filgotinib for Axial Spondyloarthritis (September 6, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Amgen Gets US Infliximab Nod
  • With Launch Years Away, FDA Touts Approval Of Fifth Humira Biosimilar
  • Bio-Thera Solutions Has China's First Adalimumab Biosimilar
  • Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line
  • Samsung Bioepis Gets US Adalimumab Nod
  • Eticovo Becomes Second Approved Enbrel Biosimilar After Under-The-Radar Review
  • Cimzia Lands New Indication For Unmet Need

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE 3 PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of ankylosing spondylitis, 2018-27
  • Figure 2: Overview of pipeline drugs for axSpA in the US
  • Figure 3: Pipeline drugs for axSpA, by company
  • Figure 4: Pipeline drugs for axSpA, by drug type
  • Figure 5: Pipeline drugs for axSpA, by classification
  • Figure 6: Cosentyx for Axial Spondyloarthritis (November 12, 2019): Phase III - PREVENT
  • Figure 7: Rinvoq for Axial Spondyloarthritis (November 12, 2019): Phase II/III - SELECT Axis 1
  • Figure 8: Cosentyx for Axial Spondyloarthritis (September 17, 2019): Phase III - PREVENT
  • Figure 9: Taltz for Axial Spondyloarthritis (April 22, 2019): Phase III - COAST-X
  • Figure 10: Taltz for Axial Spondyloarthritis (October 22, 2018): Phase III - COAST-V
  • Figure 11: Taltz for Axial Spondyloarthritis (October 20, 2018): Phase III - COAST-W
  • Figure 12: Filgotinib for Axial Spondyloarthritis (September 6, 2018): Phase II - TORTUGA (Ankylosing Spondylitis)
  • Figure 13: Key upcoming events in axSpA
  • Figure 14: Probability of success in the axSpA pipeline
  • Figure 15: Licensing and asset acquisition deals in axSpA, 2015-20
  • Figure 16: Parent patents in axSpA
  • Figure 17: Clinical trials in ankylosing spondylitis
  • Figure 18: Top 10 drugs for clinical trials in ankylosing spondylitis
  • Figure 19: Top 10 companies for clinical trials in ankylosing spondylitis
  • Figure 20: Trial locations in ankylosing spondylitis
  • Figure 21: Ankylosing spondylitis trials status
  • Figure 22: Ankylosing spondylitis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of ankylosing spondylitis, 2018-27
  • Table 2: Marketed drugs for axSpA
  • Table 3: Pipeline drugs for axSpA in the US
  • Table 4: Cosentyx for Axial Spondyloarthritis (November 12, 2019)
  • Table 5: Rinvoq for Axial Spondyloarthritis (November 12, 2019)
  • Table 6: Taltz for Axial Spondyloarthritis (November 12, 2019)
  • Table 7: Inflectra for Axial Spondyloarthritis (September 19, 2019)
  • Table 8: Cosentyx for Axial Spondyloarthritis (September 17, 2019)
  • Table 9: Taltz for Axial Spondyloarthritis (April 22, 2019)
  • Table 10: SensoReady Injector Pen for Axial Spondyloarthritis (April 9, 2019)
  • Table 11: Taltz for Axial Spondyloarthritis (October 22, 2018)
  • Table 12: Taltz for Axial Spondyloarthritis (October 20, 2018)
  • Table 13: Filgotinib for Axial Spondyloarthritis (September 6, 2018)
  • Table 14: Historical global sales, by drug ($m), 2014-18
  • Table 15: Forecasted global sales, by drug ($m), 2020-24